PBAC Public Summary Documents – November 2025
Page last updated: 20 March 2026
Public Summary Documents relating to the November 2025 PBAC meeting.
- Acalabrutinib; Tablet 100 mg; Calquence®
- Aflibercept; Solution for intravitreal injection 2 mg in 50 microlitres (40 mg per ml), Solution for intravitreal injection 2 mg in 50 microlitres (40 mg per ml) pre‑filled syringe; Eydenzelt®
- Belantamab mafodotin; Powder for injection 70 mg (50 mg per ml); Powder for injection 100 mg (50 mg per ml); Blenrep®
- Bimekizumab; Injection 320 mg in 2 ml single use pre-filled pen; Bimzelx®
- Calcipotriol with betamethasone; Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g; Actobet®
- Cetrorelix; Solution for injection 250 micrograms (as acetate) in 1 ml single use pre-filled syringe; Femvi®
- Delgocitinib; Cream 20 mg per g, 60 g; Anzupgo®
- Denosumab; Injection 60 mg in 1 ml pre-filled syringe, Injection 120 mg in 1.7 ml; Stoboclo® Osenvelt®
- Desmopressin; Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations, 5 ml; Desmomed
- Durvalumab; Solution concentrate for I.V infusion, 120 mg in 2.4 ml, Solution concentrate for I.V. infusion, 500 mg in 10 ml; Imfinzi®
- Efgartigimod alfa; Solution for subcutaneous injection 1000 mg in 5.6 ml; Vyvgart®
- Encorafenib and Binimetinib; Capsule 75 mg, Tablet 15 mg, Tablet 45 mg; Braftovi® Mektovi®
- Estradiol with Progesterone; Capsule containing estradiol 1mg (as hemihydrate) with progesterone 100mg; Bijuva®
- Fedratinib; Capsule 100 mg; Inrebic®
- Fezolinetant; Tablet 45 mg; Veoza®
- Glycopyrronium; Cream containing glycopyrronium (as bromide) 8 mg per g (2.2 mg per actuation), 50 g; Axhidrox®
- Iptacopan; Capsule 200 mg; Fabhalta®
- Lurbinectedin; Powder for I.V. infusion 2 mg; Powder for I.V. infusion 4 mg; Zepzelca®
- Omaveloxolone; Capsule 50 mg; Skyclarys® - November 2025
- Pegcetacoplan; Solution for intravitreal injection 15 mg in 0.1 ml (150 mg per ml); Syfovre®
- Pembrolizumab; Solution concentrate for I.V. infusion 100 mg in 4 ml; Keytruda®
- Pneumococcal Conjugate Vaccine, 21-Valent; Injection 0.5 mL; Capvaxive®
- Polyethylene glycol 400 with propylene glycol; Eye drops 4 mg 3 mg per ml, single dose units 0.8 ml, 28; Systane®
- Risdiplam; Tablet 5 mg; Evrysdi®
- Respiratory Syncytial Virus Vaccine; Solution for injection 50 µg in 0.5 mL pre-filled syringe; mResvia®
- Retifanlimab (Merkel cell carcinoma); Solution concentrate for I.V. infusion 500 mg in 20 mL; Zynyz®
- Retifanlimab (Squamous cell anal carcinoma); Solution concentrate for I.V. infusion 500 mg in 20 mL; Zynyz®
- Semaglutide; Solution for injection 0.25 mg in 0.5 ml single dose pre-filled pen, Solution for injection 0.5 mg in 0.5 ml single dose pre-filled pen, Solution for injection 1 mg in 0.5 ml single dose pre-filled pen, Solution for injection 1.7 mg in 0.75 ml single dose pre-filled pen, Solution for injection 2.4mg in 0.75ml single dose pre-filled pen; Wegovy®
- Tafasitamab; Powder for I.V. infusion 200 mg; Minjuvi®
- Testosterone; Transdermal cream 10 mg per mL, 50 mL; AndroFeme 1®
- Tezepelumab; Solution for injection 210 mg in 1.91 ml single dose pre-filled pen (110 mg per ml); Tezspire®
- Tocilizumab; Concentrate for injection 80 mg in 4 ml, Concentrate for injection 200 mg in 10 ml, Concentrate for injection 400 mg in 20 ml, Injection 162 mg in 0.9 ml single use pre-filled pen, Injection 162 mg in 0.9 ml single use pre-filled syringe; Avtozma®
- Tofersen; Solution for intrathecal injection 100 mg in 15 mL; Qalsody®
- Tucatinib; Tablet 50 mg, Tablet 150mg; Tukysa®
- Vedolizumab; Powder for injection 300 mg; Entyvio®
- Zanubrutinib; Tablet 160 mg; Brukinsa®
The following Public Summary Documents have been updated:
March 2025 PBAC Meeting
May 2025 PBAC meeting
July 2025 PBAC meeting
- Futibatinib: Tablet 4 mg; Lytgobi®
- Givosiran; Solution for injection 189 mg in 1 ml; Givlaari®
- Mirvetuximab soravtansine; Solution for I.V. infusion 100 mg in 20 ml vial; Elahere®
